Samata Therapeutics
Developing transformative, best-in-class medicines for patients with epilepsy, pain, and neuropsychiatric disorders.
Transformative medicines for patients with epilepsy, pain, and neuropsychiatric disorders.
We focus on neurological indications with significant unmet need.
We focus on neurological indications with significant unmet need.
We focus on neurological indications with significant unmet need.
0%
0%
Epilepsy
~40% of Epilepsy Patients have Drug-Resistant Epilepsy
0%
0%
Epilepsy
~40% of Epilepsy Patients have Drug-Resistant Epilepsy
0%
0%
Epilepsy
~40% of Epilepsy Patients have Drug-Resistant Epilepsy
0%
0%
Pain
Pain is inadequately managed in >77% of chronic pain patients
0%
0%
Pain
Pain is inadequately managed in >77% of chronic pain patients
0%
0%
Pain
Pain is inadequately managed in >77% of chronic pain patients
0%
0%
Neuropsychiatric Disorders
>30% of depression patients are treatment-resistant
0%
0%
Neuropsychiatric Disorders
>30% of depression patients are treatment-resistant
0%
0%
Neuropsychiatric Disorders
>30% of depression patients are treatment-resistant
The Problem
Current therapeutics for Epilepsy, Pain, and Neuropsychiatric Disorders provide inadequate treatment alongside serious side-effects.
Current therapeutics for Epilepsy, Pain, and many Neuropsychiatric Disorders provide inadequate treatment and come with serious side effects.
The Solution
We develop medicines with best-in-class pre-clinical efficacy by significantly reducing or eliminating adverse effects, expanding the therapeutic window for potent, clinically validated compounds.
We develop medicines with best-in-class pre-clinical efficacy by significantly reducing or eliminating adverse effects, expanding the therapeutic window for potent, clinically validated compounds.
We develop medicines with best-in-class pre-clinical efficacy by significantly reducing or eliminating adverse effects, expanding the therapeutic window for potent, clinically validated compounds.
We develop medicines with best-in-class pre-clinical efficacy by significantly reducing or eliminating adverse effects, expanding the therapeutic window for potent, clinically validated compounds.
Samata’s Development Focus
Preclinical Success with Epilepsy Identified as Lead Program
Our platform takes efficacious but toxic drugs and expands their therapeutic windows.
SMT-101
SMT-201
SMT-301
Samata’s Development Focus
We're in mid-stage preclinical studies, focusing on epilepsy as a lead program.
Our platform takes efficacious but toxic drugs and expands their therapeutic windows.
SMT-101
SMT-201
SMT-301
Samata’s Pipeline
Samata’s Pipeline
Candidate
Candidate
Candidate
Chemistry
Chemistry
Chemistry
Lead Optimization
Lead Optimization
Lead Optimization
In-Vivo Efficacy
In-Vivo Efficacy
In-Vivo Efficacy
GLP Toxicity/Scale-Up
GLP Toxicity/Scale-Up
GLP Toxicity/Scale-Up
IND
IND
IND
Indication
Indication
Indication
SMT-101
Targeted non-dissociative, fast-acting, potent, and durable Anti-Glutaminergic agent
SMT-101
Targeted non-dissociative, fast-acting, potent, and durable Anti-Glutaminergic agent
SMT-101
Targeted non-dissociative, fast-acting, potent, and durable Anti-Glutaminergic agent
Epilepsy
Epilepsy
Epilepsy
SMT-102
Targeted CB1R/CB2R engagement, durably reducing pain at the site of injury from systemic administration.
SMT-102
Targeted CB1R/CB2R engagement, durably reducing pain at the site of injury from systemic administration.
SMT-102
Targeted CB1R/CB2R engagement, durably reducing pain at the site of injury from systemic administration.
Pain
Pain
Pain
SMT-103
SMT-103
SMT-103
Undisclosed Neuropsych disorders
Undisclosed Neuropsych disorders
Undisclosed Neuropsych disorders